I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $476.3M

Company

Location

Date

Amt. (M)
(US$M)

Details


AbAg

Chilly Mazarin, France

1/19/06

€6
($7.2)

The Series B financing was led by Innoven Partners, and included Societe Generale Asset Management

Acceleron
Pharma Inc.

Cambridge, Mass.

1/5/06

$8

The financing was provided by Hercules Technology Growth Capital Inc.

Accium
BioSciences

Seattle

1/5/06

$3

The financing was provided by WRF Capital

Adlyfe Inc.

Rockville, Md.

1/17/06

$3.3

Investors in the Series A financing included Canaan Partners and Burrill Associates

Athenix Corp.

Research Triangle Park, N.C.

1/6/06

$13

Finistere Partners led the Series C round, which included Intersouth Partners, Polaris Venture Partners, Boston Millennia Partners, Hunt Ventures and Eastman Ventures

Avidex Ltd.

Oxford, UK

1/4/06

£5 ($8.8)

Syngenta AG acquired a minority equity stake in Avidex with the £5M investment

Avid Radio-
pharmaceuticals
Inc.

Philadelphia

1/5/06

$8.9

The Series A financing was led by Pfizer's Strategic Investments Group and included Lilly Ventures, RK Ventures LLC and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania

Axordia Ltd.

Sheffield, UK

1/20/06

£0.42 $0.75)

Biofusion purchased 5% of Axordia in the deal, increasing its stake to 36%

CanBas Co.
Ltd.

Numazu, Japan

1/6/06

$20

This Series D financing was co-led by NIF SMBC Ventures and Mitsui Ventures and included Nikko antfactory KK, MBL Venture Capital, Mizuho Capital, Nomura Securities and Marubeni

Cetek Corp.

Marlborough, Mass.

1/3/06

$10

Investing in the Series D financing were Argonaut Private Equity, Ventry Industries LLC, Gainesbourgh Investments, James L. Waters and Stata Ventures, all existing investors

Chlorogen Inc.

St. Louis

1/19/06

$6

The Series B financing included new investor Finistere Partners along with existing investors Burrill & Co., Prolog Ventures, Redmont Venture Partners and Harris & Harris Group

CoLucid
Pharmaceuticals

Indianapolis

1/17/06

$16.5

The Series A financing was co-led by Domain Associates and Pappas Ventures and included Triathlon Medical Ventures and Pearl Street Venture Funds

CureVac GmbH

Tubingen, Germany

1/18/06

€22 ($26.4)

New investors DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG participated in the Series B financing, which will total up to €22M

EraGen
Biosciences Inc.

Madison, Wis.

1/9/06

$12

The Series A financing was led by First Analysis Corp. and Prolog Ventures and included new investor Stonehenge Capital and existing investor Novartis Venture Fund

GlobeImmune
Inc.

Denver

1/10/06

$4.1

GlobeImmune added $4.1M to the $34.3M raised in November in a Series B financing; investors included PAC-LINK Bio Venture Capital, China Investment and Development and Yasuda Enterprise Development

Guava
Technologies
Inc.

Hayward, Calif.

1/19/06

$5.5

Guava obtained the secured debt financing from Hercules Technology Growth Capital Inc.; it also obtained a one-year credit line of $4.5M from Hercules

Hawaii Biotech
Inc.

Honolulu

1/9/06

$7.8

The Series C financing round was led by company Chairman Nick Mitsakos and included private investors

ImmunoBiology
Ltd.

Cambridge, UK

1/23/06

£5.5 ($9.8)

The Series C financing was led by Inventages Venture Capital Investments Inc. and included Biosciences VTC and existing investors Avlar BioVentures, Oxford Technology VCT, Generics Asset Management and Yorkshire Fund Managers

Ipsat
Therapies

Helsinki, Finland

1/25/06

€3 ($3.7)

The funding was provided by InnovationsKapital

MAP Pharmaceuticals
Inc.

Mountain View,
Calif.

1/25/06

$25.25

The Series C financing was led by Brookside Capital and included previous investors Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Bay City Capital and Skyline Ventures, as well as Alexandria Real Estate Equities

Metabolon Inc.

Research Triangle Park, N.C.

1/18/06

$8

The Series B financing was led by Sevin Rosen Funds and included existing investors The Aurora Funds and The Trelys Funds and new investor Harris & Harris Group

Nabriva
GmbH

Vienna, Austria

1/31/06

€42 ($50.7)

Nabriva was spun off from Sandoz GmbH; Nomura Phase4 Ventures led the Series A round, which included HBM, the Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund

Novacea Inc.

South San Francisco

1/4/06

$25

Investors in the $25M second tranche of the Series C financing included Apax Partners, Domain Associates, New Enterprise Associates, ProQuest Investments, Versant Ventures and Sofinnova Ventures; $35M was raised in the first Series C tranche in January 2004

Ocera
Therapeutics
Inc.

San Diego

1/17/06

$14.5

The Series A financing was co-led by Domain Associates and Thomas, McNerney & Partners

OcuCure
Therapeutics

Roanoke, Va.

1/31/06

ND

The undisclosed investment was provided by the Carilion Biomedical Institute

OptiNose A/S

Oslo, Norway

1/9/06

ND

WFD Ventures Ltd. provided the undisclosed funding

Proacta Inc.

San Diego

1/24/06

$12

Investing in the Series A financing were GSB Ventures, Endeavour i-Cap, No8 Ventures, Alta Partners, Genentech Inc. and F. Hoffmann-La Roche Ltd.

Protein Sciences Corp.

Meriden, Conn.

1/9/06

$6

Investing in the round were Diamyd Medical AB, Pacific Rim Ventures Co. Ltd. and a family fund

Supernus
Pharmaceuticals
Inc.

Rockville, Md.

1/12/06

$27.5

New Enterprise Associates and OrbiMed Advisors provided funding for the new company, which acquired the product formulation and development business of Shire Laboratories Inc.

Symphogen
A/S

Copenhagen, Denmark

1/8/06

$25

Company said it completed the initial closing of a Series D financing; investors included LD Pensions, Essex Woodlands Health Ventures, Scandinavian Life Science Venture, Novo A/S, Vaekstfonden and Takeda Research Investment Inc.

Theregen Co.

San Francisco

1/17/06

$1.5

Sanderling Ventures invested in the Series A financing and would add more if milestones are reached

TiGenix NV

Leuven, Belgium

1/5/06

€16 ($19.4)

The Series B financing round was led by ING Corporate Finance, and included HSS Ventures, ITX Corp., Banque Generale de Luxembourg, Baekelands Fonds 2, SRIW and Partners@Venture, as well as all existing investors

Tioga
Pharmaceuticals
Inc.

San Diego

1/6/06

$24

Founding investor Forward Ventures led the Series A financing, which also included New Leaf Venture Partners and BB Biotech Ventures II

Vasopharm
Biotech GmbH

Wurzburg, Germany

1/30/06

€9.7 ($11.7)

The Series B financing was led by EMBL Ventures and included other new investors Bayern Kapital and KfW and existing investors Future Capital AG, Entrepreneurs Fund, 3i Group Investments LP and private investors

XDx Inc.

South San Francisco

1/5/06

$26.5

Duff, Ackerman & Goodrich led the Series E round, which included Intel Capital and existing inves- tors Kleiner Perkins Caufield & Byers, Texas Pacific Group Ventures, the Sprout Group, Burrill & Co., Integral Capital Partners and Bay Area Equity Fund

Xytis Inc.

Irvine, Calif.

1/9/06

$24.5

The Series B round was led by Sanderling Ventures and included Atlas Venture, Ventech and CDC Entreprises Innovation; the company resulted from the merger of Xytis Pharmaceuticals Ltd. and Remergent Inc.


Notes:

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

No Comments